Galectin Therapeutics Company Description

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases.

Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.

Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration.

The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011.

Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.